A prospective study assessed the effect of Serenita in the care of type 2 diabetes patients. Serenita encourages deep diaphragmatic breathing and coherence breathing. The single-arm pilot study included 9 adults (18 years of age or older) who had type 2 diabetes for at least 1 year. Collected measures included HbA1c, triglycerides (TG), fasting plasma glucose (FPG), 7-point daily glycemic profile, weight, and blood from baseline to week 8. Compliance with app use was also monitored in addition to completing the SF-12 questionnaire, which examines lifestyle. Baseline assessment included a physical and gathering the patient’s medical history. Dietary counseling was provided in accordance to the American Diabetes Associations (ADA) guidelines by a registered dietician. The patients received weekly check-in calls over the course of 8 weeks, and monthly calls until 16 weeks. At 16 weeks, patients returned to the clinic where anthropometric measures, blood tests, and 7-point glucose measurements were reassessed. It was found that the patients had an improvement in weight, blood pressure, and glycemic profile while receiving standard care and using the Serenita app. (Munster-Segev, Fuerst, Kaplan, & Cahn. 2017. https://mhealth.jmir.org/2017/5/e75/)
5.00
Acceptable
4.64
